In November 2019, Drug Science launched Project Twenty21 – Europe’s first and biggest national medical cannabis registry. The project was set up for simple reasons. Even after legislation around cannabis based medical products (CBMPs) was changed by the UK Government, too many people are still unable to access these treatments. The cost of these medications  …

This Drug Science research was published in the British Medical Journal Open, you can download the full report here. In November 2018 when the UK made cannabis-based products for medicinal use (CBPMs) legal most people assumed these would immediately be made available to patients, but they were wrong. In the year since almost no National  …

About Project Twenty21 Project Twenty21 is a registry aiming to monitor the health outcomes of 20,000 patients using cannabis based medicinal products (CBMPs), creating the largest body of evidence in Europe for the safety and efficacy of CBMPs. Drug Science hope that the findings of Project Twenty21 will provide evidence for NHS funding where the  …

Update from the Director Project Twenty21 Roadmap [/vc_column_text] In November 2019, Project Twenty21 was announced to the public. This announcement marked the very beginning of the project.  Project Twenty21 is not a clinical trial. Instead, it is a registry/database which is being developed to address the challenge of controlling the cost of medication, supporting doctors,  …

Drug Science launched Europe’s first and biggest national medical cannabis registry, called Project Twenty21, on the 7th November 2019. Project TWENTY21 aims to enrol 20,000 patients by the end of 2021, creating the largest body of evidence for the effectiveness and tolerability of medical cannabis – with an aim to demonstrate to policymakers that medical  …